Syndax Pharmaceuticals is looking for a Health Outcomes Liaison - West
At Syndax, we are determined to realize a future in which people with cancer live longer and better than ever before. Syndax Pharmaceuticals is a commercial stage biopharmaceutical company developing an innovative pipeline of cancer therapies.
The Role:
The Health Outcomes Liaison (HOL) is a field-based medical colleague responsible for providing therapeutic area/product expertise for a designated therapeutic, with a primary focus on organized customers, including but not limited to Regional Payers, Key Opinion Leaders (KOLs), Specialty Pharmacy Providers (SPPs) and Population Based Decision Makers (PBDM). The responsibilities of the role are to contribute to Syndax’s ability to:
Provide therapeutic area/product expertise for regional and other Medical Affairs and/or clinical development needs as approved by HOL leadership (e.g. formulary presentations, field force training, organized customer projects/collaborations, scientific congress participation, Syndax-sponsored research site / investigator interactions, TA/product expertise for Syndax-sponsored studies, IST inquiries etc.).
Key Responsibilities:
Desired Experience/Education and Personal Attributes:
Location: Syndax has an office in New York City and has a dispersed workforce across the United States.
Syndax offers a total compensation and rewards package that is among the most competitive in the industry. Base pay is just one element of our package and is determined within a range based on several factors including market data, experience, qualifications, demonstrated skills, relevant education or training, travel requirements and internal equity. Our overall package also includes an equity offering, annual target bonuses, and an outstanding benefits program. The anticipated annualized salary range for this role is $240,000 - 270,000.
About Syndax:
Syndax Pharmaceuticals is a commercial-stage biopharmaceutical company developing an innovative pipeline of cancer therapies. Highlights of the Company's pipeline include Revuforj® (revumenib), an FDA-approved menin inhibitor, and Niktimvo™ (axatilimab-csfr), an FDA-approved monoclonal antibody that blocks the colony stimulating factor 1 (CSF-1) receptor. Fueled by our commitment to reimagining cancer care, Syndax is working to unlock the full potential of its pipeline and is conducting several clinical trials across the continuum of treatment. For more information, please visit www.syndax.com/ or follow the Company on X (formerly Twitter) and LinkedIn.
Syndax Pharmaceuticals is an equal opportunity employer and will not discriminate against any employee or applicant on the basis of age, color, disability, gender, national origin, race, religion, sexual orientation, veteran status, or any classification protected by federal, state, or local law.
#California #Washington #Arizona #Nevada #Oregon
#LI-remote
Rocket Companies
Canonical
Lighthouse Autism Center
Omni Calculator
American Income Life Insurance Company